Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
Chronic Myeloid Leukemia (CML) is a myeloproliferative disease characterized by the presence of the Philadelphia chromosome (translocation between chromosomes 9 and 22), resulting in the formation of the hybrid BCR-ABL protein. Currently, the treatment of CML patients is performed with imatinib mesy...
Saved in:
Main Authors: | Caroline Regina de Jesus (Author), Lee I-Ching (Author), Teresinha de Jesus Carvalho Neiva (Author), Cidônia de Lourdes Vituri (Author) |
---|---|
Format: | Book |
Published: |
Universidade de São Paulo,
2011-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al. -
Multiple eruptive dermatofibromas secondary to imatinib mesylate in a patient with chronic myeloid leukemia
by: Francisco J Lira-Valero, et al.
Published: (2021) -
Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
by: Yan Chen, et al.
Published: (2020) -
Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia
by: Emanuelle S. Dal Ponte, et al.
Published: (2017) -
Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013)